> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Califf Backs Evidence Generation Report
- URL: https://www.fdaweb.com/califf-backs-evidence-generation-report/
- Published: 2023-11-15T12:00:00.000Z
- Updated: 2026-09-14T14:16:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155798

FDA commissioner **Robert Califf** says “the time is right” to address the post-market evidence generation recommendations in a new Reagan-Udall Foundation [report](https://www.fdaweb.com/improve-post-market-evidence-generation-report/). In the prepared text of a speech to be given to an unidentified group, Califf [says](https://www.einnews.com/pr%5Fnews/668573182/remarks-by-dr-robert-califf-on-the-reagan-udall-foundation-s-report-and-recommendations-on-evidence-generation-11-14-2023?ref=fdaweb.com) the post-market questions “stretch beyond the direct purview of FDA and take us into territory that intersects multiple federal agencies, provider organizations, clinicians, and payers, and patients have much at stake in getting this right. The net result of the fragmentation of responsibility in the post-market phase is that we have no national system to generate the evidence we need to optimize the screening, diagnosis, and treatment among the multitude of medical products on the market. Yet we continue to spend over $4.3 trillion for health outcomes that are inferior to other high-income countries, exemplified by our significantly shorter life expectancy compared with peers.”

If the report’s recommendations were to be implemented effectively, Califf says, it could open evidence generation for nutrition and dietary supplements. “The report is a compilation of practical tactics that have been promoted in previous reports,” he says, “but the comprehensive nature of the 30 recommendations gives us an excellent list from which to reform the system.”

He discusses several of the major recommendations and concludes that while FDA will continue to improve the premarket clinical trial system for medical products, “now is the time to make major renovations to our post-market systems. Technology is no longer our limitation. All of us would benefit from more knowledge of which medical products should be used for which patients and populations at a given point in their clinical journey.”